Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer - Li, Qiong; Zhang, Daoxiang; Chen, Xiaoying; He, Lei; Li, Tianming; Xu, Xiaoping; Li, Min (Scientific reports, 2015)
Keywords: 13/109; 13/2; 13/31; 13/44; 13/89; 14/19; 14/63; 64/60; 692/308/1892; 692/4028/67/1059/602; 82/29; 82/80; 96/1; Antineoplastic Agents - pharmacology; Brain tumors; Carrier Proteins - genetics; Cell Line; Cell Line, Tumor; Cell Nucleus - drug effects; Cell Nucleus - genetics; Clinical trials; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; Drug Resistance, Neoplasm - genetics; Enzyme inhibitors; Epidermal growth factor; Epidermal growth factor receptors; ErbB Receptors - genetics; Gefitinib; Glioma; HCT116 Cells; HEK293 Cells; HT29 Cells; Humanities and Social Sciences; Humans; Inhibitor drugs; Lung cancer; Membrane Proteins - genetics; multidisciplinary; Protein Kinase Inhibitors - pharmacology; Protein-tyrosine kinase; Pyruvate kinase; Pyruvic acid; Quinazolines - pharmacology; Science; siRNA; Stat3 protein; STAT3 Transcription Factor - genetics; Targeted cancer therapy; Thyroid Hormone-Binding Proteins; Thyroid Hormones - genetics; Transcription; Transcriptional Activation - genetics; Up-Regulation - genetics